Can the CSL share price regain its 52-week high in 2022?

One broker is optimistic on the outlook for CSL shares.

| More on:
Two happy scientists analysing test results in a lab

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • After last seeing a 52-week high last year, CSL shares have been stuck in the mud lately
  • The healthcare giant's last all-time high was way back in 2020
  • But one broker is tipping big things for the CSL share price

It's been many moons since we last saw a 52-week high for the CSL Limited (ASX: CSL) share price. Today, shares of the ASX 200 healthcare giant are going for $296.90 each at the time of writing, down by 0.58% over the session so far.

But we have to backtrack to November last year to find the last time this company was hitting new highs. Back in late November, we saw the CSL share price hit a high of $319.78 per share.

That is the company's reigning 52-week high – a level we haven't seen the company even approach since. In fact, it was only three months or so later that CSL was hitting a new 52-week low of $240.10 per share.

So today, CSL shares are close to the middle of this 52-week range.

This begs the question: what's next for the CSL share price? Will we be heading back to the company's 52-week high in 2022?

Is the CSL share price heading back to its 52-week high in 2022?

Well, one ASX broker reckons CSL is in with more than a chance. As my Fool colleague James covered just yesterday, broker Citi is expecting big things from the ASX 200 healthcare share. Citi likes what it sees with CSL's recent acquisition of Vifor Pharma and its development pipeline.

The broker rated CSL a buy, with a 12-month share price target of $340. Not only is that target well above CSL's current 52-week high, but it is also tantalisingly close to the company's all-time high of $342.75 a share.

Indeed, if this price target came to pass, it would mean an upside of more than 14% on the current CSL share price. But since this target is a 12-month one, we can't say the broker is expecting a new high by the end of this year.

Even so, no doubt investors will welcome that news. But we'll have to wait and see if Citi's projections prove accurate, as always.

In the meantime, CSL shareholders can now look forward to receiving the company's final dividend of $1.758 per share which will be paid out next month on 5 October.

At the current CSL share price, this ASX 200 healthcare share has a market capitalisation of around $144 billion, with a dividend yield of 1.04%.

Motley Fool contributor Sebastian Bowen has positions in CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »